中藥ETF(159647)升超2%,機構看好中藥板塊
中藥板塊上升,佛慈制藥、新天藥業、香雪製藥升停,中藥ETF(159647)升超2%。消息面上,佛慈制藥擬對主營中成藥產品的出廠價進行調整,平均提價幅度為9%。德邦證券研報指出,當前醫藥已經處於中長期配置的窗口,其中中藥性價比更為突出,估值較低,業績相對較好,潛在催化劑較多。湘財證券認為,中藥行業相關政策呈現出深度上聚焦行業痛點、廣度上覆蓋全產業鏈的特點,圍繞政策特點,中藥行業或呈現結構性分化,符合政策特點的企業有望表現突出。中藥ETF(159647),場外聯接(A類:016891;C類:016892)
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.